Blueprint vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical measurement and therapy outcomes platform for mental health providers, Austin TX, raised $8M+. Automates outcome tracking and progress notes for therapists.
About
Blueprint is an Austin, Texas-based clinical technology company founded in 2018 that provides mental health providers with a measurement-based care platform designed to automate outcomes tracking, streamline progress note documentation, and improve the quality and consistency of mental health treatment. The company has raised over $8 million and serves thousands of therapists and group practices seeking to implement structured clinical measurement without significant workflow disruption.\n\nBlueprint's platform automates the collection of validated clinical questionnaires (such as PHQ-9, GAD-7, and PCL-5) before or between sessions, presents clinicians with outcome trend visualizations at the point of care, and generates draft progress notes based on session data. The AI-assisted note generation feature is particularly valued by clinicians who spend significant time on documentation after sessions, with Blueprint reducing note completion time while improving clinical documentation quality and compliance.\n\nThe company distributes through direct sales to individual therapists and group practices, and is expanding partnerships with group practice management platforms and EHR vendors to embed its measurement capabilities into existing clinical workflows. Blueprint competes with Greenspace Health and Osmind in the measurement-based care space, and with Nabla and Heidi Health in the AI-assisted clinical documentation market. The intersection of outcomes accountability and administrative relief positions Blueprint as both a quality improvement tool and a therapist burnout reduction solution.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.